Cargando…
Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
Cardiovascular disease (CVDs) is the first killer of human health, and it caused up at least 31% of global deaths. Atherosclerosis is one of the main reasons caused CVDs. Oral drug therapy with statins and other lipid-regulating drugs is the conventional treatment strategies for atherosclerosis. How...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315585/ https://www.ncbi.nlm.nih.gov/pubmed/37404681 http://dx.doi.org/10.3389/fbioe.2023.1205751 |
_version_ | 1785067533509853184 |
---|---|
author | Luo, Ting Zhang, Zhen Xu, Junbo Liu, Hanxiong Cai, Lin Huang, Gang Wang, Chunbin Chen, Yingzhong Xia, Long Ding, Xunshi Wang, Jin Li, Xin |
author_facet | Luo, Ting Zhang, Zhen Xu, Junbo Liu, Hanxiong Cai, Lin Huang, Gang Wang, Chunbin Chen, Yingzhong Xia, Long Ding, Xunshi Wang, Jin Li, Xin |
author_sort | Luo, Ting |
collection | PubMed |
description | Cardiovascular disease (CVDs) is the first killer of human health, and it caused up at least 31% of global deaths. Atherosclerosis is one of the main reasons caused CVDs. Oral drug therapy with statins and other lipid-regulating drugs is the conventional treatment strategies for atherosclerosis. However, conventional therapeutic strategies are constrained by low drug utilization and non-target organ injury problems. Micro-nano materials, including particles, liposomes, micelles and bubbles, have been developed as the revolutionized tools for CVDs detection and drug delivery, specifically atherosclerotic targeting treatment. Furthermore, the micro-nano materials also could be designed to intelligently and responsive targeting drug delivering, and then become a promising tool to achieve atherosclerosis precision treatment. This work reviewed the advances in atherosclerosis nanotherapy, including the materials carriers, target sites, responsive model and treatment results. These nanoagents precisely delivery the therapeutic agents to the target atherosclerosis sites, and intelligent and precise release of drugs, which could minimize the potential adverse effects and be more effective in atherosclerosis lesion. |
format | Online Article Text |
id | pubmed-10315585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103155852023-07-04 Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms Luo, Ting Zhang, Zhen Xu, Junbo Liu, Hanxiong Cai, Lin Huang, Gang Wang, Chunbin Chen, Yingzhong Xia, Long Ding, Xunshi Wang, Jin Li, Xin Front Bioeng Biotechnol Bioengineering and Biotechnology Cardiovascular disease (CVDs) is the first killer of human health, and it caused up at least 31% of global deaths. Atherosclerosis is one of the main reasons caused CVDs. Oral drug therapy with statins and other lipid-regulating drugs is the conventional treatment strategies for atherosclerosis. However, conventional therapeutic strategies are constrained by low drug utilization and non-target organ injury problems. Micro-nano materials, including particles, liposomes, micelles and bubbles, have been developed as the revolutionized tools for CVDs detection and drug delivery, specifically atherosclerotic targeting treatment. Furthermore, the micro-nano materials also could be designed to intelligently and responsive targeting drug delivering, and then become a promising tool to achieve atherosclerosis precision treatment. This work reviewed the advances in atherosclerosis nanotherapy, including the materials carriers, target sites, responsive model and treatment results. These nanoagents precisely delivery the therapeutic agents to the target atherosclerosis sites, and intelligent and precise release of drugs, which could minimize the potential adverse effects and be more effective in atherosclerosis lesion. Frontiers Media S.A. 2023-06-19 /pmc/articles/PMC10315585/ /pubmed/37404681 http://dx.doi.org/10.3389/fbioe.2023.1205751 Text en Copyright © 2023 Luo, Zhang, Xu, Liu, Cai, Huang, Wang, Chen, Xia, Ding, Wang and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Luo, Ting Zhang, Zhen Xu, Junbo Liu, Hanxiong Cai, Lin Huang, Gang Wang, Chunbin Chen, Yingzhong Xia, Long Ding, Xunshi Wang, Jin Li, Xin Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
title | Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
title_full | Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
title_fullStr | Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
title_full_unstemmed | Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
title_short | Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
title_sort | atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315585/ https://www.ncbi.nlm.nih.gov/pubmed/37404681 http://dx.doi.org/10.3389/fbioe.2023.1205751 |
work_keys_str_mv | AT luoting atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT zhangzhen atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT xujunbo atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT liuhanxiong atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT cailin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT huanggang atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT wangchunbin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT chenyingzhong atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT xialong atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT dingxunshi atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT wangjin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms AT lixin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms |